Background: The risk for type 1 diabetes mellitus (T1DM) and celiac disease (CD) is related to human leukocyte antigen (HLA) DQA1, DQB1 and DRB1 loci. Unfortunately, HLA typing has been too difficult and costly for frequent use. Automated genotyping focused on risk alleles could provide access to HLA typing in diagnostic evaluations, epidemiological screening and contribute to preventive strategies. Methods: A sequence specific primer amplification method requiring a total of four PCR reactions, one restriction enzyme digestion and a single electrophoretic step provides low to medium resolution typing of DQA1, DQB1 and DRB1 using Applied Biosystems 3730 DNA analyzer. The method was validated using 261 samples with genotypes determined using a reference method. Results: Specific fluorescent DQA1, DQB1 and DRB1 amplicons were of expected size. Concordance with the reference method was 100% for DQA1 and DQB1 alleles and 99.8% for DRB1 alleles. Conclusions: We have developed a high throughput HLA typing method that accurately distinguishes risk alleles for T1DM and CD. This method allows screening of several thousand samples per week, consuming 32 ng of DNA template, low reagent volumes and minimal time for data review. Clin Chem Lab Med 2009;47:1489-95.
Introduction
The prevalence of type 1 diabetes mellitus (T1DM, OMIM %222100) is 0.05%-0.4% in the general population of Europe and the US (1-3), while the prevalence of celiac disease (CD, OMIM ࠻212750) is close to 1% and possibly higher in Northern European countries (3) (4) (5) . Both diseases occur during early childhood, cluster in families, and significantly affect health and family life-styles. Thus, risk assessment for siblings and other family members is frequently requested. Inter-action of environmental exposure with a genetic predisposition for autoimmune disease is well documented (6) (7) (8) (9) (10) . The most important genes contributing to disease susceptibility are located in the human leukocyte antigen (HLA) class II region on chromosome 6p21.3. For both diseases, a very limited number of HLA DQA1 and DQB1 alleles appear to be prerequisite for an immune reaction.
Numerous studies have demonstrated that DQB1*02 or *0302 expressed with DQA1*05 or DQA1*03, respectively, confer a genetic risk for CD (11, 12) . About 90%-95% of patients with CD carry the DQB1*02 allele together with DQA1*05 (encoded either in cis or trans), compared to a prevalence of 20%-30% in the general population (13) . Most of the remaining 5%-10% have a DQ haplotype comprised of DQA1*03 and DQB1*0302 (11, 14, 15) , and nearly no patients with CD lack both of these DQ risk combinations. Studies have shown an increased risk in individuals homozygous for DQB1*02 (15) (16) (17) and an HLA-DQ risk gradient has been established for CD (Table 1) (18) . Thus, screening for DQB1*02 and *0302 allows very sensitive, but not specific, identification of subjects at risk (19) .
The situation is somewhat more complex, but similar for T1DM, with risk also associated with DQB1*0201 and *0302 alleles (20) (21) (22) . However, this risk appears to be modified by the accompanying DRB1 alleles (21, (23) (24) (25) (26) . A continuous gradient from highly predisposing to very protective haplotypes has been demonstrated in various studies (24, 27, 28) . DRB1*04-DQB1*0302 or DRB1*03-DQB1*0201 are present in 90%-95% of patients who develop T1DM compared to 40%-45% of normal controls. Compound heterozygotes carrying both of these haplotypes confer an increased risk compared to homozygotes for either haplotype. DRB1*15-DQB1*0602, found in -1% of patients with T1DM and 20% of the general population, has a protective association with the disease (1, 29) . Table 2 shows the HLA risk association with T1DM. In both CD and T1DM, the presence of a known risk allele indicates significantly increased relative risk, still lacking specificity. However, absence of all known risk alleles has a high negative predictive valuethus, obviating the need for additional diagnostic testing.
Testing for HLA risk can be performed using commercial kits such as Olerup SSP DQ (Genovision/ Qiagen, Oslo, Norway), Delfia ᮋ HLA hybridization assay (Perkin Elmer Life and Analytic Sciences Wallac, Turku, Finland) or Dynal RELIீ SSO HLA typing kit (Dynal Biotech Ltd, Bromborough, UK). These methods require many reactions and/or multiple steps. We present a novel automated high-throughput PCR-SSP (sequence specific priming) method for HLA-DRB1, DQA1 and DQB1 genotyping, optimized for capillary electrophoresis using Applied Biosystems 3730 or 3130xl DNA Analyzers (Applied Biosystems, Foster City, CA, USA), with a specific focus on risk alleles for T1DM and CD.
Materials and methods

DNA samples
DNA samples derived from affected sib-pair families or trios were obtained following informed consent from participants from five continents enrolled in the type 1 Diabetes Genetic Consortium (T1DGC) (30) . The project was approved by Ethical Review Boards in each participating country. A sample panel of 261 residual recoded DNA samples and 12 nontemplate controls (NTC) used for proficiency testing within the T1DGC HLA genotyping network were available with permission for use to validate this method. The samples have been genotyped by three accredited laboratories using a proprietary high-resolution PCR-based sequence specific oligonucleotide probe linear array (Roche Molecular Systems, Pleasanton, CA, USA). There was 100% interlaboratory consensus at these three loci, described by Mychaleckyj et al.
(manuscript submitted).
HLA-DQA1, DQB1 and DRB1 typing
DNA sequences of the second exon of HLA class II genes were obtained from the IMGT/HLA database (31) . Intronic sequences were obtained from genebank sequences listed in Bergströ m et al. (32) and Kotsch et al. (33) . Sequence specific primers corresponding to exon 2 of the DQA1 and DQB1 genes, and to intron 1, exon 2 and intron 2 of the DRB1 gene, were designed using Oligo 6.69 software (Molecular Biology Insights Inc, Cascade, CO, USA). Four different primer mixes were used, each containing at least one locus specific common primer labeled with a fluorescent dye specific for the locus (NED, a yellow fluorescent color, for DQA1, VIC, a green fluorescent color, for DQB1 and FAM, a blue fluorescent color, for DRB1) and several allele specific primers. The common DRB1 primer was placed 39 to numerous microsatellite repeats to provide distinct class-specific amplicon sizes. Special care was taken to prevent co-amplification of the other existing DRB genes. All primers and primer mixes are listed in Table 3 .
All primers were diluted to a concentration of 2.5 mM.
Each PCR reaction contained 2 mL 4 ng/mL DNA, 0.6 mL tems), 2 mL primer mix (Table 3) , and H 2 O to a final volume of 6 mL.
PCR reactions were performed in barcoded 96-or 384-well plates (Abgene, Epsom, UK) using a GeneAmp PCR system 9700 (Applied Biosystems). The DQB1 *02/*03/*04, DRB1 mix I and DRB1 mix II were amplified following initial denaturation at 958C for 10 min, with 45 cycles at 948C for 1 min, 668C for 30 s and 728C for 1 min, and a final 10 min at 728C. DQA1/DQB1 *05/*06 was amplified using the same conditions, with the exception of a 648C annealing temperature.
Following amplification, 7.5 mL of a digestion mixture containing 1.25 mL Buffer Bq (10 mM Tris-HCl, pH 7.5; 10 mM MgCl 2 , 0.1 mg/mL BSA), 0.1 mL of the restriction endonu- Module, POP-7 polymer and the G5 dye set. Analysis time for a 96 well plate is ;1 h. Some analyses were also performed using a 3130xl Genetic Analyzer, requiring 3 h per run. Detected fragment sizes were correlated to the LIZ-labeled internal standard peaks on the x-axis. Each HLA locus is represented by a specific fluorescent dye and each analyzed allele is represented by a specific size. Automated allele calling was performed using GeneMapper v 3.0 (Applied Biosystems). All allele calls were verified by manual inspection of the GeneMapper images and haplotype checks were performed before final allele designation.
Results
The NED-labeled DQA1 specific amplicons, VIClabeled DQB1 specific amplicons and FAM-labeled DRB1 specific amplicons were easily distinguished by GeneMapper. Figure 1 shows 
DQ allelic assignments
The sizes of all allele specific amplicons agreed with those expected and no overlap occurred, as shown in Supplemental data Figure 1 . Although DQA1*06 cannot be distinguished from DQA1*04, and heterozygous DQA1*04/*05 and *05/*06 samples cannot be distinguished from homozygous DQA1*05/*05, such ambiguities can be resolved by haplotype analysis together with DRB1 and DQB1 data, choosing the most preferential allele identification as DR and DQ alleles exist in common although not entirely consistent linkage. Similarly, some heterozygous combinations of DQB1*03 alleles appear ambiguous, but can be distinguished using haplotype association.
DRB1 allelic assignments
Whereas most DRB1 alleles produced expected amplicon lengths, some displayed size variation due to a variable microsatellite in intron 2. Thus, a range of fragment sizes occurred with evident overlap between some allelic groups, see Supplemental data Figure 2 . This method was able to distinguish the T1DM susceptible DRB1*04 subtypes *0401, *0402, *0404 and *0405 from the neutral or protective subtypes DRB1 *0403 and *0407. Of the 191 alleles typed as DRB1*04 susceptible, one sample was DRB1*0419, which is very uncommon and the disease association is not known. DRB1*0403, *0407, *07, *09 and *10 alleles produced fragments of distinctive lengths. DRB1*03, *08, and *16 alleles could be easily identified by referring to DR-DQ haplotypes. The DRB1*11, *12, *13, *14 and *15 alleles, which are generally neutral, were designated DRB1*X as some overlap occurred. The T1DM protective DRB1*1401 and *1501 alleles could be differentiated from the DRB1*X group by size and haplotype association in 95% (82/86) of the cases. All analyzed haplotypes and the corresponding results, presumed by known linkage disequilibrium, are shown in Supplemental data Table 2 .
Discussion
The major clinical importance of the HLA DR-DQ region is well established for CD and T1DM, and other associations within the HLA region are being investigated for rheumatoid arthritis, Morbus Addison and other diseases. Due to the extreme variability seen in this region, very large study populations are required to attain statistical power of association with other specific diseases.
To meet current local demands for an HLA method for the study of T1DM and CD, we developed a high throughput SSP genotyping method. Our method requires a maximum of 32 ng DNA templates, four PCR reactions, one restriction enzyme digestion and a single electrophoretic step using an automated DNA analyzer and automated allele assignment.
As specific risk alleles for these diseases are well established, high resolution of all neutral alleles is unnecessary. If a focus on other alleles is necessary, the method can be modified by exchange or addition of new primers and validation.
Since concordance of the DQA1 and DQB1 typing was 100%, and all DQ alleles associated with CD, i.e., DQA1*05-DQB1*02 and DQA1*03-DQB1*0302 could be distinguished from other alleles, this method is sufficiently sensitive and specific for clinical use to confirm or exclude the possibility of CD. Additionally, DQB1 *02 homozygosity could be determined in the absence of another DQB1 allele since at least one primer for every DQB1 allele group (i.e., *02, *03, *04, *05, *06) was included in the analysis.
The positive predictive value of the presence of these risk alleles is low. Thirty to forty percent of the Caucasian population carries at least one of these DQ combinations, and only 1%-4% of these individuals have CD (10) . In contrast, the negative predictive value of their absence is )99.5% (12) . Therefore, HLA genotyping can be useful for precluding the necessity for further invasive diagnostic testing or to exclude risk in relatives. It is estimated that most cases of CD remain undiagnosed, and untreated CD can cause long-term health problems. Thus, targeted screening in families of CD probands could identify such undiagnosed individuals and prevent lifelong symptoms and complications (4) .
As for CD, the DQB1*02 and/or *0302 alleles are present in nearly all T1DM cases. By including the restriction enzyme digestion step of DRB1*04 and *01 PCR products, DRB1*01 could be differentiated from other DRB1 alleles and DRB1 subtypes *0401, *0402, *0404, *0405 associated with T1DM disease risk could be differentiated from *0403 and *0407 which are considered protective, even when present on the same ''high-risk'' DQA1*03-DQB1*0302 haplotype (24) . Also, the less common DRB1*08-DQA1* 04-DQB1*04 and DRB1*01-DQA1*01-DQB1*05 risk alleles could be easily distinguished by this assay. Although allele frequencies and relative risks vary significantly in different populations and publications (24, 27, 28) , essentially no cases lacking the above named alleles are seen in T1DGC cases (data unpublished).
A high-throughput screening assay such as that presented here could be useful in population studies such as ongoing prospective neonatal screening programs assessing T1DM risk (9, 34, 35) . Also, analysis of HLA-DR-DQ alleles may be important for discriminating between subjects at high or intermediate risk from antibody positive individuals carrying protective haplotypes (36) .
In our validation study using 261 samples from families with T1DM from five continents, DRB1 typing made one incorrect identification only. Even though the sample panel originates from a T1DM study, 28 of the most common Caucasian haplotypes are represented in the dataset, covering all haplotypes with a frequency )0.3% in the general Caucasian population. In addition, several rare haplotypes are included in the dataset. However, we would caution that the efficiency of some markers in the screening protocol may depend on the population being studied, as allele frequencies and microsatellite repeats vary among different populations. It is therefore wise to validate this method against samples with known genotypes in different settings.
We developed an economical, high throughput HLA typing method that accurately distinguishes risk alleles for T1DM and CD with a degree of accuracy of 100% for DQA1, 100% for DQB1 and 99.8% for DRB1 genotyping. Simultaneous detection of DRB1, DQA1 and DQB1 alleles allows resolution of many potential ambiguities by reference to common haplotype associations. Although the method is not intended for matching of donors and recipients in the context of transplantation, it provides equal or better resolution compared with many available commercial kits and is well suited for clinical screening (e.g., as a negative predictor for CD or T1DM). The multiplex concept of this basic PCR-SSP capillary electrophoresis method is amenable to adaptation for many different disease associations.
By using locus specific fluorescent markers and capillary electrophoresis, multiple PCR products from all three loci can be automatically resolved by size, analyzed and typed in a single step. With a total requirement of 32 ng DNA template, HLA typing becomes possible using dried blood spots for DNA template. The low reagent costs and rapid interpretation allows analysis of high-risk alleles in epidemiological as well as clinical settings.
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